Compare Spotify Technology (SPOT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs TransMedics Group Inc — how do they compare? Spotify Technology trades at $528.22 (market cap $108.22B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Spotify Technology is far larger — about 39.5× TransMedics Group Inc's market cap, and Spotify Technology is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spotify Technology for 111 Days and TransMedics Group Inc for 24 Days on average.
| SPOT | TMDX | |
|---|---|---|
Market Cap | $108.22B | $2.74B |
Volume | 1,655,796 | 949,331 |
Sector | Media | Health |
52-Week High | $692.04 | $150.42 |
52-Week Low | $412.75 | $61.99 |
Typical Hold Time | 111 Days | 24 Days |
Enterprise Value | $98.23B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $529.14, up 3.16% with strong technical momentum above key support levels. The company demonstrates robust fundamental performance with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent earnings show mixed results with two beats and one miss, while analyst consensus remains strongly bullish with a $606.50 price target. Technical indicators show bullish moving averages but neutral oscillators, with RSI suggesting potential overbought conditions near-term.
Spotify presents a compelling growth story with expanding profit margins and strong cash flow generation. Key opportunities include continued subscriber growth and new monetization tools, while risks involve competitive pressures and execution challenges. The stock trades near the lower end of analyst targets, offering potential upside if execution continues.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
